ARIDIS PHARMACEUTICALS INC

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch ARDS and buy or sell other stocks, ETFs, and their options commission-free!

About ARDS

Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using human monoclonal antibodies, or mAbs, to treat infections. The company was founded by Eric J. 

CEO
Vu L. Truong
CEOVu L. Truong
Employees
37
Employees37
Headquarters
Los Gatos, California
HeadquartersLos Gatos, California
Founded
2003
Founded2003
Employees
37
Employees37

ARDS Key Statistics

Market cap
0.00
Market cap0.00
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
24.71K
Average volume24.71K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$0.05
52 Week high$0.05
52 Week low
$0.00
52 Week low$0.00

Stock Snapshot

As of today, ARIDIS PHARMACEUTICALS INC(ARDS) shares are valued at $0.00. The company's market cap stands at 0.

On 2026-07-02, ARIDIS PHARMACEUTICALS INC(ARDS) stock opened at —, reached a high of —, and a low of —.

ARIDIS PHARMACEUTICALS INC(ARDS) shares are trading with a volume of 0, against a daily average of 24.71K.

During the past year, ARIDIS PHARMACEUTICALS INC(ARDS) stock moved between $0.00 at its lowest and $0.05 at its peak.

During the past year, ARIDIS PHARMACEUTICALS INC(ARDS) stock moved between $0.00 at its lowest and $0.05 at its peak.

People also own

Based on the portfolios of people who own ARDS. This list is generated using Robinhood data, and it’s not a recommendation.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.